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Abstract 
Background: In this observational trial, data were collected on the effectiveness and tolerability/safety of a nasal 
spray containing tramazoline and essential oils (trade name Rhinospray® Plus) used for symptomatic treatment of 
acute rhinitis due to common cold.
Methods: The trial was performed in 300 children, adolescents and adults, who were to be treated with Rhinospray® 
Plus for up to 4 times per day for up to 10 days. Primary endpoints were the change from baseline to final visit in the 
mean of three single symptom scores (blocked nose, sneezing, and runny nose) and the mean improvement in two 
quality-of-life parameters (ability to perform normal daytime activities and quality of sleep).
Results: A total of 108 children, 30 adolescents and 162 adults were treated with Rhinospray® Plus. No patient dis-
continued prematurely. There was a mean reduction of 2.0 ± 0.6 (standard deviation) in nasal symptom scores from 
baseline to final visit; 297 of 300 of patients (99.0 %) reported an improvement. The mean value for improvement in 
quality-of-life parameters was 1.3 ± 0.5. Improvement in daytime activities was reported by all 300 patients (100.0 %) 
and in quality of sleep by 292 patients (97.4 %). Effectiveness and tolerability were rated as ‘very good’ or ‘good’ by 
95.4 % and 97.4 % of patients, respectively; the investigators rated effectiveness and tolerability as ‘very good’ or ‘good’ 
for 97.4 % and 100.0 % of patients, respectively. No adverse events were reported.
Conclusions: Community-based patients reported a relief in acute rhinitis symptoms and improvement in quality of 
life as a result of treatment with Rhinospray® Plus. Treatment was well-tolerated.
© 2015 Katona et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Findings
Background
A troublesome feature of common cold is acute rhinitis 
(inflammation of the nasal mucous membranes resulting 
in congestion, rhinorrhoea, and sneezing). Nasal conges-
tion negatively impacts daily activities and is a common 
complaint in children and adults who visit otorhinolaryn-
gologists [1]. Congestion can be treated with topical 
nasal sprays containing imidazoline derivatives [1], which 
stimulate alpha-adrenergic receptors and induce vaso-
constriction in the nose and paranasal sinuses, thereby 
reducing swelling and mucus production.
Rhinospray® Plus is a topical nasal spray containing tra-
mazoline hydrochloride monohydrate and essential oils 
(eucalyptol, levomenthol and camphor); it is effective and 
well-tolerated in treatment of nasal congestion caused by 
acute rhinitis due to common cold or hay fever [1–5]. Rhi-
nospray® Plus is suitable for adults and children 6 years of 
age and older. The recommended dose is a single puff of 
spray (0.07 mL spray containing 0.09 mg tramazoline) into 
each nostril, up to 4 times daily for up to 7 days [6]. Based 
on available data and clinical experience, however, treat-
ment durations of 10–15 days are acceptable.
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The goal of this observational study was for patients 
and investigators to assess effectiveness and tolerabil-
ity/safety of Rhinospray® Plus treatment of acute nasal 
congestion caused by common cold. The study was con-
ducted in a community (real-life) setting, with emphasis 
on quality-of-life measures.
Methods
Patients who presented with cold symptoms to one of 
four outpatient centres, received a clinical diagnosis of 
acute rhinitis, and had not previously used Rhinospray® 
Plus were eligible for enrolment. Patients provided 
informed consent (for minors, this was provided by a 
parent/guardian). Exclusion criteria included allergic 
rhinitis, contraindications to Rhinospray® Plus, partici-
pation in another trial, pregnancy/breastfeeding, or ina-
bility to cooperate.
Patients underwent two ambulatory clinic visits, at 
baseline and on the day after treatment was terminated. 
At the baseline visit, patients rated three nasal symp-
toms (blocked nose, sneezing and runny nose) on a 0–3 
scale (0 =  absent, 1 = mild, 2 = moderate, 3 =  severe) 
[7]. Treatment with Rhinospray® Plus was to start on the 
same day as the baseline visit. Patients were instructed 
to use one puff of Rhinospray® Plus per nostril up to 4 
times daily for up to 10 days. They also received a diary 
in which to record medication use, onset and duration 
of action of Rhinospray® Plus, and daily nasal symptom 
scores.
At the final visit, patients rated nasal symptoms and 
improvement in two quality-of-life parameters (ability to 
perform normal daytime activities and quality of sleep) 
on a 1–4 scale (1 = strong improvement, 2 = moderate 
improvement, 3 = weak improvement, 4 = no improve-
ment), as well as overall effectiveness and tolerability on 
a 1–4 scale (1 = very good, 2 = good, 3 = fair, 4 = poor). 
The patients also answered a questionnaire assessing 
comfort of application and effect of the essential oils. 
Investigators recorded their assessments of effectiveness 
and tolerability and patients’ spontaneous reporting of 
adverse events.
Primary endpoints were the change from baseline to 
final visit in the mean of nasal symptom scores and the 
mean improvement in quality-of-life parameters. Sec-
ondary endpoints were the change from baseline to 
final visit in single nasal symptom scores, the improve-
ment in each quality-of-life parameter, and the patients’ 
and investigators’ assessment of treatment effectiveness. 
Tolerability/safety was evaluated on the basis of adverse 
events and patients’ and investigators’ assessment of tol-
erability. Additional parameters included onset of action 
and duration of the treatment effect, and evaluation of 
comfort of application and the essential oil component of 
the spray. Data were analysed with descriptive statistics. 
Safety analyses included all treated patients and effective-
ness analyses included all patients for whom a final visit 
was recorded. The study was approved by the Medical 
Research Council, Scientific and Research Committee, 
Reference number: 40683-2/2013/EKU (482/2013), by 
the Hungarian Regulatory Authority (Reference number: 
OGYI/30633-6/2013) and was registered in the clinical-
trials.gov database under the identifier NCT01971086.
Results
Three hundred patients were enrolled and treated; for 
all patients, a final visit was recorded. No patient discon-
tinued treatment. Of the 300 patients, 162 (54.0 %) were 
adults (age 18 and over), 30 (10.0  %) were adolescents 
(age 13–17) and 108 (36.0  %) were children (age 6–12). 
Additional patient characteristics are provided in Table 1.
Primary endpoints
Including all patients, the mean symptom score was 
2.1 ± 0.6 at baseline and 0.1 ± 0.3 at the final visit; the 
mean decrease was 2.0  ±  0.7 (Table  2). Of the 300 
patients, 297 (99.0 %) reported a decrease in mean symp-
tom score. The median symptom score was 0 at the final 
visit (Fig.  1). The mean improvement in the quality of 
life parameters was 1.3 ±  0.5 (Table  2), and all patients 
(100 %) reported an improvement on at least one quality-
of-life measure. 
Secondary endpoints
At the final visit the mean blocked nose, sneezing and 
runny nose scores were 0.2 ± 0.4, 0.0 ± 0.2 and 0.1 ± 0.4, 
respectively; mean decreases were 2.4  ±  0.8, 1.4  ±  0.9 
and 2.2  ±  0.8, respectively (Table  3). The median and 
third quartile scores were 0 for all nasal symptoms at the 
final visit. For improvement in daily activities, the mean 
score at final visit was 1.3  ±  0.5 and for improvement 
in sleep was 1.3 ±  0.6. Most patients reported a strong 
improvement in daytime activities (77.0 %) and in sleep 
quality (78.7  %; Figs.  2, 3). Overall, 97.3  % of patients 
rated the effectiveness of Rhinospray® Plus as ‘very good’ 
or ‘good’ (Fig.  4), and 95.4  % of investigators rated the 
effectiveness as ‘very good’ or ‘good’ (Table 3).   
Additional parameters
The majority of patients (92.4 %) reported that treatment 
started to work within 5 min or fewer. More than half of 
patients (52.0  %) reported a duration of effect between 
4 and 8  h (Table  4). For application comfort, 76.7  % of 
patients indicated it was comfortable as could be and 
57.7 % stated that the spray did not flow into the larynx. 
For the essential oils, 56.7  % of patients indicated that 
they gave the spray a pleasant feeling, 52.0  % that they 
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promoted free breathing and 48.7  % that they provided 
a clear, cool feeling. Patients’ diaries indicated a gradual 
improvement of symptoms over time, with only 36.7  % 
of patients still using Rhinospray® Plus on day 7 (Fig. 5). 
On Day 7, 51.3 % of patients continued to reported nasal 
symptoms (51.2 % of adults, 53.7 % of children and 43.3 % 
of adolescents).
Safety endpoints
Mean duration of treatment was 7.1 days; there were no 
relevant differences based on patient age (Table 5). Over-
all, 97.7 % of patients (Fig. 6) and 100.0 % of investigators 
rated the treatment tolerability as ‘very good’ or ‘good’ 
(Table 5). There were no adverse events reported.
Discussion
Observational studies play an important role in assess-
ment of benefit/risk profiles of medicinal products, 
and they are often requested by health and regulatory 
authorities. Such studies add important information to 
results obtained in ‘classical’ phase III clinical trials [8]. 
A strength of the current observational study is that it 
was performed under real-life conditions in patients 
presenting from the community. Interpretation of the 
Table 1 Demographics and baseline characteristics, treated set
a Concomitant diagnosis is listed only for those categories including >5 % of patients
b Concomitant medications are listed only for those categories including >5 % of patients
Children Adolescents Adults Total
Patients, N (%) 108 (36.0) 30 (10.0) 162 (54.0) 300 (100)
Mean age in years (SD) 8.4 (2.0) 14.6 (1.3) 42.1 (15.9) 27.2 (20.0)
Sex, N (%)
 Female 37 (34.3) 15 (50.0) 94 (58.0) 146 (48.7)
 Male 71 (65.7) 15 (50.0) 68 (42.0) 154 (51.3)
Height (SD) 134 (15.1) 167 (16.9) 173 (9.8) 158 (22.1)
Weight (SD) 31.8 (10.2) 59.6 (16.1) 75.3 (18.2) 58 (25.5)
Mean days since symptom onset (SD) 1.3 (1.2) 1.1 (1.9) 1.4 (1.9) 1.3 (1.7)
Baseline mean symptom score (SD) 2.1 (0.6) 2.1 (0.6) 2.1 (0.6) 2.1 (0.6)
Pretreated with other medications, N (%) 8 (7.4) 6 (20.0) 30 (18.5) 44 (14.7)
Concomitant diagnosis, N (%)a 48 (44.4) 8 (26.7) 45 (27.8) 101 (33.7)
Ear and labyrinth disorders 22 (20.4) 4 (13.3) 5 (3.1) 31 (10.3)
Respiratory, thoracic and mediastinal disorders 21 (19.4) 2 (6.7) 3 (1.9) 26 (8.7)
Vascular disorders 0 (0.0) 0 (0.0) 18 (11.1) 18 (6.0)
Gastrointestinal disorders 4 (3.7) 0 (0.0) 13 (8.0) 17 (5.7)
Concomitant medications, N (%)b 49 (45.4) 7 (23.3) 45 (27.8) 101 (33.7)
Antibiotics, N (%) 31 (28.7) 3 (10.0) 4 (2.5) 38 (12.7)
Smoker, N (%) 0 (0.0) 0 (0.0) 23 (14.2) 23 (7.7)
Table 2 Primary endpoints, full analysis set
Children Adolescents Adults Total
Patients, N (%) 108 (36.0) 30 (10.0) 162 (54.0) 300 (100)
Symptom score of three nasal indices
 Mean score at final visit (SD) 0.1 (0.3) 0.1 (0.3) 0.1 (0.2) 0.1 (0.3)
 Mean change from first visit (SD) −1.9 (0.7) −1.9 (0.7) −2.0 (0.6) −2.0 (0.7)
 Median score at final visit (min, max) 0 (0, 1.0) 0 (0, 1.3) 0 (0, 2) 0 (0, 2)
 Median change from first visit (min, max) −2 (−3, 0) −2 (−3, 0.7) −2 (−3, 0.7) −2 (−3, 0.7)
Improvement in quality of life
 Mean improvement (SD) 1.2 (0.5) 1.2 (0.5) 1.3 (0.5) 1.3 (0.5)
 Median improvement (min, max) 1 (1, 3) 1 (1, 3) 1 (1, 3) 1 (1, 3)
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results is limited by the uncontrolled trial design; con-
sequently, efficacy cannot be assessed in the strict sense. 
However, the study aimed to determine whether Rhino-
spray® Plus benefited nonideal patients (that is, patients 
who administered the trial medication themselves in a 
home setting, including those with comorbid conditions 
and those who were pretreated or cotreated with other 
medications). The results indicate that this was so: for 
more than 95 % of patients—by both their own and the 
investigators’ assessments—effectiveness and tolerability 
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Fig. 1 Quartile scores, median, minimum and maximum scores, and 
mean values for the total of the three nasal symptoms at Visit 1 (V1) 
and Visit 2 (V2), full analysis set. For children and for all patients at Visit 
2, quartile 1, median, and quartile 3 values were zero
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Fig. 3 Improvement in quality of sleep
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Fig. 4 Patients’ assessment of effectiveness
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were ‘very good’ or ‘good’. An improvement in at least 
one quality-of-life parameter was reported by 100  % of 
patients. The fact that no patient discontinued treatment 
is an additional indication of the acceptability of Rhino-
spray® Plus.
Furthermore, the study included children and ado-
lescents, who are commonly excluded from controlled 
clinical trials. When comparing data collected for the 
different age groups involved in the trial, effectiveness 
results (primary endpoints) were comparable between 
adults, children and adolescents. For quality of life 
parameters, even better results were observed in chil-
dren and adolescents than for adults, especially with 
respect to quality of sleep. Similarly, treatment was 
even better tolerated by children and adolescents than 
adults.
Colds are self-limited illnesses; it may be argued that 
patients would experience symptomatic improvement 
with or without treatment over the time span of the 
trial. The current study was not designed to determine 
whether treatment with Rhinospray® Plus shortened 
the duration of symptoms when compared with no 
Table 3 Secondary endpoints, full analysis set
Children Adolescents Adults Total
Patients, N (%) 108 (36.0) 30 (10.0) 162 (54.0) 300 (100)
Blocked nose
 Mean score at final visit (SD) 0.2 (0.5) 0.2 (0.5) 0.2 (0.4) 0.2 (0.4)
 Mean change from first visit (SD) −2.2 (0.9) −2.2 (0.9) −2.5 (0.7) −2.4 (0.8)
 Median score at final visit (min, max) 0 (0, 2) 0 (0, 2) 0 (0, 2) 0 (0, 2)
 Median change from first visit (min, max) −2 (−3, 1) −2 (−3, 0) −2 (−3, 0) −2 (−3, 1)
Sneezing
 Mean score at final visit (SD) 0.1 (0.2) 0.1 (0.3) 0.0 (0.2) 0.0 (0.2)
 Mean change from first visit (SD) −1.4 (1.0) −1.5 (0.9) −2.0 (0.6) −1.4 (0.9)
 Median score at final visit (min, max) 0 (0, 1) 0 (0,1) 0 (0, 2) 0 (0, 2)
 Median change from first visit (min, max) −1 (−3, 0) −1 (−3, 0) −1 (−3, 2) −1 (−3, 2)
Runny nose
 Mean score at final visit (SD) 0.1 (0.3) 0.2 (0.5) 0.1 (0.4) 0.1 (0.4)
 Mean change from first visit (SD) −2.2 (0.8) −2.0 (0.8) −2.1 (0.9) −2.2 (0.8)
 Median score at final visit (min, max) 0 (0, 2) 0 (0, 2) 0 (0, 2) 0 (0, 2)
 Median change from first visit (min, max) −2 (−3, 0) −2 (−3, 0) −2 (−3, 1) −2 (−3, 1)
Improvement in daily activities
 Mean score at final visit (SD) 1.2 (0.5) 1.1 (0.3) 1.3 (0.5) 1.3 (0.5)
 Median score at final visit (min, max) 1 (1, 3) 1 (1, 2) 1 (1, 3) 1 (1, 3)
Improvement in sleep
 Mean score at final visit (SD) 1.2 (0.7) 1.3 (0.8) 1.3 (0.5) 1.3 (0.6)
 Median score at final visit (min, max) 1 (1, 4) 1 (1, 4) 1 (1, 3) 1 (1, 4)
Patients’ effectiveness assessment, N (%)
 Very good 95 (88.0) 24 (80.0) 103 (63.6) 222 (74.0)
 Good 11 (10.2) 5 (16.7) 54 (33.3) 70 (23.3)
 Fair 2 (1.9) 1 (3.3) 5 (3.1) 8 (2.7)
 Poor 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Investigators’ effectiveness assessment, N (%)
 Very good 91 (84.3) 24 (80.0) 97 (59.9) 212 (70.7)
 Good 14 (13.0) 5 (16.7) 55 (34.0) 74 (24.7)
 Fair 2 (1.9) 1 (3.3) 9 (5.6) 12 (4.0)
 Poor 1 (0.9) 0 (0.0) 0 (0.0) 1 (0.3)
 Missing 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.3)
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treatment. However, literature comparisons suggest this 
may be so. In this trial, 51 % of adults, 54 % of children 
and 43 % of adolescents continued to report one or more 
nasal symptoms on day 7. This compares with a surveil-
lance study in children in which 86 % of patients still had 
nasal symptoms after 6 days or more [9], and a prospec-
tive study in adults in which 72  % of patients still had 
at least one nasal symptom on day 7 [10]. It should also 
be noted that in the current study, more than 75  % of 
patients (all age groups) were free of nasal symptoms at 
the final visit (mean treatment duration: 7.1 days). These 
promising data should be further assessed in controlled 
clinical trials.
The results of this study indicate that Rhinospray® 
Plus is well-tolerated and comfortable to apply. Commu-
nity-based patients reported a relief in nasal cold symp-
toms and improvement in quality of life as a result of 
treatment.
Table 4 Onset of  treatment effect and  duration of  treat-
ment effect, full analysis set
Children Adolescents Adults Total
Patients, N (%) 108 (36.0) 30 (10.0) 162 (54.0) 300 (100)
Time until treatment took effect, N (%)
 After less than 1 min 21 (19.4) 6 (20.0) 27 (16.4) 54 (18.0)
 Between 1 and 3 min 59 (54.6) 15 (50.0) 63 (38.9) 137 (45.7)
 Between 3 and 5 min 24 (22.2) 7 (23.3) 55 (34.0) 86 (28.7)
 After more than 
5 min
3 (2.8) 2 (6.7) 17 (10.5) 22 (7.3)
 Information missing 1 (0.9) 0 (0.0) 0 (0.0) 1 (0.3)
Duration of treatment effect, N (%)
 Fewer than 4 h 30 (27.8) 7 (23.3) 57 (35.2) 94 (31.3)
 Between 4 and 8 h 56 (51.9) 14 (46.7) 86 (53.1) 156 (52.0)
 Between 8 and 10 h 21 (19.4) 8 (26.7) 17 (10.5) 46 (15.3)
 More than 10 h 1 (0.9) 0 (0.0) 2 (1.2) 3 (1.0)
 Information missing 0 (0.0) 1 (3.3) 0 (0.0) 1 (0.3)
Fig. 5 Summary of number of patients on treatment over time
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